Cocrystal Pharma, Inc. Common Stock
COCP
COCP: Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
moreShow COCP Financials
Recent trades of COCP by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by COCP's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication May. 25, 2021
-
Patent Title: Inhibitors of hepatitis c virus polymerase Mar. 16, 2021
-
Patent Title: Inhibitors of hepatitis c virus polymerase Nov. 05, 2019
-
Patent Title: Inhibitors of hepatitis c virus polymerase Oct. 01, 2019
-
Patent Title: Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer Jul. 03, 2018
-
Patent Title: Potent and selective inhibitors of hepatitis c virus Apr. 03, 2018
-
Patent Title: Potent and selective inhibitors of hepatitis c virus Mar. 27, 2018
-
Patent Title: Potent and selective inhibitors of hepatitis c virus Nov. 10, 2015
-
Patent Title: Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections Nov. 03, 2015
-
Patent Title: Hcv ns3 protease inhibitors May. 26, 2015
Federal grants, loans, and purchases
Followers on COCP's company Twitter account
Number of mentions of COCP in WallStreetBets Daily Discussion
Recent insights relating to COCP
Recent picks made for COCP stock on CNBC
ETFs with the largest estimated holdings in COCP
Flights by private jets registered to COCP